AstraZeneca has entered a collaboration agreement with insitro, a California‑based biotechnology company focused on machine learning, to discover and develop new therapies for metabolic dysfunction‑associated steatohepatitis (MASH, often referred to as NASH) and a range of cardiomyopathies.
Financial terms and royalties
Under the deal, AstraZeneca will pay insitro a $40 million upfront fee. In addition, insitro may become eligible for further development and commercial milestone payments totaling approximately $1.46 billion, plus single‑digit percentage royalties on future sales.
Focus areas of the partnership
The multi‑year collaboration concentrates on two areas with significant unmet medical need: MASH/NASH, a serious liver disease, and cardiomyopathies, a group of heart muscle disorders. Both areas have lacked effective therapies in part because researchers have struggled to pinpoint the precise biological mechanisms that drive these diseases.
insitro’s platform and division of work
Insitro will apply its Virtual Human platform, which combines lab‑grown cellular models with machine learning to uncover causal biological mechanisms of disease. The company will advance AstraZeneca‑selected targets from the discovery phase to preclinical drug‑candidate stage. After that point, AstraZeneca will fund and conduct clinical trials.
Context within insitro’s industry expansion
The agreement represents another milestone in insitro’s expansion of pharma partnerships. The company recently broadened its collaboration with Bristol Myers Squibb to expand a portfolio of targets for amyotrophic lateral sclerosis (ALS), and it has partnered with Eli Lilly to develop AI models that predict pharmacological properties of small‑molecule drugs.
Why this matters
Sharon Barr, AstraZeneca’s Executive Vice President for Biopharmaceutical R&D, said selecting new targets for the development pipeline is one of the most difficult aspects of R&D. She noted that when a biological pathway or target is already reported in leading scientific journals, it is no longer novel; combining AI tools with experienced researchers can reduce the number of molecules that need laboratory testing, lower uncertainty, and accelerate the discovery of effective therapies.
Source and note
This article is based on a Reuters report. An AI assistant contributed to preparing this text; a human journalist edited and verified the final content.
Tags: Reuters, artificial intelligence, pharmaceuticals, R&D, biotechnology, AstraZeneca, insitro, Eli Lilly, Bristol Myers Squibb, MASH, cardiomyopathy
